Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy

from Hospital and Internal Medicine Podcast · host Gil Porat, M.D., FACP, CPT

The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). Now let us dig a bit more into those headlines.

Episode metadata supplied by the publisher feed · Published Jan 27, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Heart Failure with Preserved Ejection Fraction (Diastolic CHF) and SGLT-2 Inhibitor Therapy

0:00 11:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Hospital and Internal Medicine Podcast?

This episode is 11 minutes long.

When was this Hospital and Internal Medicine Podcast episode published?

This episode was published on January 27, 2022.

Can I download this Hospital and Internal Medicine Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!